Tools
Counseling Patients on Bariatric Surgery for Obesity
Introduction
Obesity is defined as a body mass index (BMI) of 30 kg/m², and severe obesity is defined as a BMI of greater than 40 kg/m². The prevalence of obesity is approximately 40% in the United States, and is more common in those between the ages of 40 and 59. The prevalence of severe obesity is 9.4% and is higher among women.[1] Global obesity prevalence is estimated at 37%, accounting for 2.8 million deaths per year, and has doubled since 1990.[2] The societal burden of obesity is multifaceted, with a profound impact on the economy and the overall well-being of the population.
Obesity is associated with conditions such as cardiovascular disease, type 2 diabetes mellitus, metabolic dysfunction, dyslipidemia, obstructive sleep apnea, liver disease, and cancer. Obesity is one of the leading causes of preventable death, according to global obesity statistics (Global Obesity).[3] Inflammation plays a significant role in the comorbid conditions and physical manifestations of obesity. Chronic inflammation is, in part, mediated by adipose cytokines such as interleukin-6, leading to decreased wound healing and disrupted innervation through impaired signal transduction. Interleukin-6 and inflammation also affect neurotransmitters, cerebellar signaling, and endothelial cell signaling to the brain.
Obesity is multifactorial and is caused by lifestyle factors, medications, comorbidities, heritable conditions, and psychosocial issues. Results from meta-analyses have shown that caloric restriction alone usually does not lead to sustained weight loss. Furthermore, pharmacologic advances in weight management do not offer the same degree of long-term success as surgical intervention. The class of glucagon-like peptide-1 receptor agonists offers improved weight loss compared with other medical therapies, but bariatric surgery consistently yields superior long-term weight loss and more successful remission of obesity-related comorbidities. Bariatric surgery is most effective for those with a BMI greater than 40 kg/m². Coupled with counseling and education focused on lifestyle modification within multimodal bariatric programs, bariatric surgery offers a long-term remedy for obesity-related systemic metabolic dysfunction.[4][5][6][7][8]
Persons with obesity are risk-stratified using BMI, waist circumference, and assessment of comorbidities. Counseling and postoperative management are critical components of comprehensive care for patients with obesity. Goals of preoperative counseling include promoting sustained behavior modification and conducting a thorough risk-benefit analysis to support patient-centered, shared decision-making. Another essential component of preoperative counseling is educating patients about the short- and long-term risks of bariatric surgery, including steps to mitigate and recognize potential complications. Nutritional guidelines before and after bariatric surgery are another critical subject covered both preoperatively and postoperatively.[9]
Function
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Function
Bariatric surgery is the most effective evidence-based treatment for all classes of obesity. The 2022 guidelines issued by the American Society for Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity and Metabolic Disorders include modifications from the 1991 National Institutes of Health Guidelines:
- Recommend bariatric surgery for individuals with a BMI ≥ 35 kg/m², regardless of the presence or severity of comorbidities.
- Consider bariatric surgery for individuals with metabolic disease and a BMI of 30 kg/m² to 34.9 kg/m², particularly following an ineffective trial of nonsurgical therapy.
- Adjusted BMI thresholds for Asian patients: A BMI ≥ 25 kg/m² indicates clinical obesity, and a BMI ≥ 27.5 kg/m² may qualify for bariatric surgery.
These revised guidelines underscore a shift towards earlier surgical intervention for obesity and its associated metabolic comorbidities, acknowledge the limitations of BMI as a sole diagnostic criterion, and recognize variation in physiological responses to obesity across populations.[10]
Before surgery, all patients should undergo a thorough, interdisciplinary preoperative assessment to optimize surgical outcomes and minimize potential complications. A comprehensive evaluation quantitatively diagnoses all obesity-related comorbidities and prepares patients for the physiological and psychological effects of bariatric surgery in the immediate postoperative period and beyond. Critical components include stabilizing coexisting medical conditions and supporting lifestyle modifications such as tobacco cessation. Equally important is addressing any preoperative nutritional deficiencies, providing education on postoperative nutritional risks, and ensuring psychological readiness for surgery.[10][11]
Bariatric surgeries are broadly categorized as restrictive, malabsorptive, or a combination. Restrictive techniques, such as laparoscopic sleeve gastrectomy, reduce stomach size, leading to early satiety. Malabsorptive procedures such as biliopancreatic diversion with or without duodenal switch modify nutrient absorption.[12] The Roux-en-Y gastric bypass (RYGB) combines restrictive and malabsorptive elements.[13] Laparoscopic sleeve gastrectomy and RYGB currently account for approximately 90% of all bariatric procedures.[10] Endoscopic procedures, including intragastric balloons and endoscopic sleeve gastroplasty, are becoming more common and are associated with a lower risk.[14]
Early postoperative complication rates, including 30-day mortality, readmission, and reoperation, are similar for RYBG and laparoscopic sleeve gastrectomy.[15] Enhanced recovery protocols have reduced the length of hospital stay. Some patients who undergo a sleeve gastrectomy or endoscopic procedure are discharged the same day or within 24 hours.[16][17] A BMI greater than 50 kg/m² is associated with a longer hospital stay.[18] Long-term outcomes differ between the 2 main procedures. RYGB typically leads to more sustained weight loss, more frequent resolution of type 2 diabetes mellitus, and improved control of gastroesophageal reflux disease compared with laparoscopic sleeve gastrectomy. However, laparoscopic sleeve gastrectomy has fewer significant late complications. Patients usually return to work 2 to 3 weeks following a laparoscopic sleeve gastrectomy and RYGB, and return to normal activities within 4 to 6 weeks.[19]
Bariatric care involves an interdisciplinary team, including surgeons, nutritionists, primary care clinicians, and psychologists. In the United Kingdom, guidance from the National Institute for Health and Care Excellence (NICE) emphasizes interdisciplinary assessment and ongoing support. (NICE: Overweight and Obesity management-NG246 https://www.nice.org.uk/guidance/ng246/chapter/Medicines-and-surgery). Patients should be counseled on surgical risks, benefits, and potential complications to make an informed decision. Patients should be aware that long-term care is important to identify early malnutrition, anastomotic leaks, ulcers, or obstruction. Monitoring includes nutritional assessment, medication review, and ongoing physical and psychological support.[10]
Patients must remain on lifelong vitamin supplementation and require periodic laboratory testing, including serum parathyroid hormone, vitamin D, calcium, vitamin B12, folate, iron, magnesium, and phosphate levels, as well as a complete blood cell count.[20][21] Patients who are discharged from the bariatric clinic are referred to support groups.[20] The Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program devised a surgical risk-benefit calculator, which helps extrapolate predicted improvements in comorbidities at the one-year postoperative mark. The application of this tool helps guide informed consent by calculating short-term risks and longer-term benefits.[22][23]
Issues of Concern
Malnutrition is a significant long-term risk factor following bariatric surgery, particularly after malabsorptive procedures.[24] Clear postoperative dietary guidelines must be provided with timely interval follow-up. Patients should take lifelong vitamin supplementation, but study findings show declining compliance at 5 months, with further reductions by 2 to 3 years.[25] Vitamin B12 and iron are the most commonly encountered deficiencies, especially among menstruating or pregnant women. Required supplements include vitamins A, B12, C, and D; calcium, magnesium, phosphate, iron, folic acid, zinc, copper, selenium, and thiamine. Some patients may require enteral supplementation via jejunostomy.[24][26]
Postoperative complications can be due to surgical complications, insufficient weight loss, or postoperative weight regain. Revision surgery may be necessary for ulcers, anastomotic leaks, or psychological intolerance to bariatric anatomy. Revision surgery is high-risk due to the possibility of adhesions and altered anatomy. Weight regain following surgery is multifactorial and remains an area of active study, but often involves resumption of high-calorie intake despite surgical changes.
The reduction in food intake can be circumvented by consuming calorically dense liquids such as ice cream and milkshakes. Weight regain is most common following sleeve gastrectomy, underscoring the importance of continued postoperative care.[27] Depressive disorders, binge eating, and uncontrolled snacking have been associated with poor weight loss outcomes. Accordingly, most bariatric programs require a preoperative psychological assessment.[28] Psychological intervention is most effective when instituted postoperatively, and cognitive behavioral therapy targeting eating behaviors is the most effective intervention.[25]
There has been a recent expansion of advanced pharmacologic therapies for obesity, including glucagon-like peptide-1 (GLP-1) and dual incretin agents that activate both GLP-1 and glucose-dependent insulinotropic polypeptide receptors. These medications suppress glucagon, stimulate insulin release, and improve satiety and may be used in conjunction with or before bariatric surgery. An understanding of their mechanisms of action and patient selection criteria is important to optimize their use in the perioperative period.[29][30][31]
The signs and symptoms of acute postoperative and long-term complications can be subtle. Vigilance is required in the acute postoperative period. Postoperative tachycardia, even if mild, can be an indication of bleeding or an anastomotic leak. Nausea and anorexia occurring several days after surgery or later may indicate an internal hernia. Any new or concerning symptoms merit close assessment, as delays in diagnosis can lead to severe clinical consequences, including death. Hypoglycemia typically peaks 1 to 3 years postoperatively, as reported in results from a multicenter cohort study.[32] Other surgical complications include fistulae, ulcers, deep vein thrombosis, cholestasis, and intestinal obstruction. Patients with a gastric remnant and symptoms who undergo computed tomography should sip oral contrast while on the table to optimize visualization of the upper gastrointestinal tract anatomy.[33]
Results from a multicenter study of bariatric surgical complications identified bleeding and malnutrition as the most common complications, followed by anastomotic leaks, marginal ulcers, and obstruction. Bleeding incidence was higher in those older than 70 years. Anastomotic leak incidence was highest in those undergoing RYBG and among those with preoperative gastrointestinal reflux disease. Complications were more frequent at surgery centers that perform 50 or fewer bariatric surgeries per year.[34] Some complications are managed nonoperatively, whereas others mandate urgent surgical exploration. Anastomotic leaks are handled using a combination of drainage and endoscopic, laparoscopic, and open surgical approaches. Nutritional deficiencies are primarily treated with supplementation, and occasionally with modification or reversal of bariatric anatomy. Anastomotic leaks and nutritional deficits are directly associated with increased mortality.[34]
Clinical Significance
All levels of obesity alter metabolism, increase health risks, profoundly affect psychosocial and physiological health, and result in lost productivity and higher treatment costs. To date, bariatric surgery is the most effective treatment offering improved longevity and remission of obesity-related comorbidities. Bariatric surgery is associated with significant reductions in cardiovascular disease, dyslipidemia, obstructive sleep apnea, arthritis, some cancers, hepatic steatosis, and gastroesophageal reflux disease.[35][36] Type 2 diabetes mellitus, previously considered a chronic, progressive disease, with up to 50% of patients requiring insulin by 10 years, may improve or enter remission following bariatric surgery. Although some studies report similar results with low-calorie diets of 900 calories per day, these effects are not usually sustained beyond 3 months.[37] Results from a British meta-analysis demonstrated complete resolution of type 2 diabetes mellitus in 78.1% of patients.[38] There is significant evidence of reduced disease burden and increased life expectancy following bariatric surgery.[39][40]
The metabolic dysfunction that arises in all stages of obesity has several systemic consequences. Metabolic dysfunction–associated steatotic liver disease is present in many patients with obesity, ranging from hepatic steatosis to metabolic pathologies, including diabetes mellitus, insulin resistance, hyperlipidemia, and increased risk of cirrhosis and hepatocellular carcinoma. Hepatic dysfunction is also associated with generalized memory impairment, increased confusion, and decreased concentration. While the precise etiology, whether oxidative stress, cerebral metabolic dysfunction, or other cause, has not been elucidated, bariatric surgery is associated with an improvement in cognitive function that parallels weight loss and improved hepatic function. The most significant neurological recovery was associated with a postoperative decline in hemoglobin A1c, glucose, and triglyceride levels.[7] Obesity is also associated with reduced left ventricular function. An improvement in myocardial work and efficiency, and reductions in dyspnea, have been observed following metabolic surgery.[41][42] Markers of aging and oxidative stress, such as C-reactive protein and tumor necrosis factor levels, may decline following bariatric surgery.[43]
According to results from a cohort study, patients who derive the most benefit from bariatric surgery are those with a BMI greater than 40 kg/m² and obesity-related comorbidities. However, all persons with a BMI greater than 30 kg/m² demonstrate improved quality of life and reduced risk factors, such as type 2 diabetes mellitus and cardiovascular disease. Patients who may be ineligible for bariatric surgery based on BMI criteria may benefit from reduced future disease risk and improved overall health. When BMI criteria are not met, consideration of surgical candidacy may also incorporate quality-of-life factors. Preoperative counseling promotes both quality of life and the goal for ideal body weight when setting expectations, possibly enhancing motivation for behavioral modifications.[9][44]
The United Kingdom National Bariatric Surgical Registry revealed that hospital mortality from bariatric surgery is low (0.7%). The overall morbidity was 3.1%, and the most commonly included postoperative vomiting, atelectasis, pneumonia, fever, infection, and electrolyte imbalance. Another analysis of approximately 5.6 million patients from 2012 to 2018 found that morbidity and mortality rates following bariatric surgery were also low. The most frequent complications identified were infection, thromboembolism, and renal failure.[45]
Other Issues
Obesity prevalence is increasing globally, and the associated health concerns contribute to a growing worldwide economic burden. Since 1990, global obesity rates have doubled in the adult population and quadrupled in adolescents (WHO 2025 Obesity statistics). The United States has the highest rates of obesity globally, now surpassing 40%. Effective obesity treatment requires highly trained specialists across multiple disciplines. Increasing demand for surgical treatment overwhelms bariatric centers and resources. Bariatric centers need specialized equipment, including beds, operating tables, and radiographic capabilities.[1]
The cost of medical care for patients with obesity is approximately 30% greater than for those with a BMI greater than 30 kg/m², and higher for those with a BMI greater than 35 kg/m². The median procedural costs from a nationwide inpatient cohort were $9219 for a laparoscopic adjustable gastric band, $10,537 for sleeve gastrectomy, and $12,543 for gastric bypass. Even if revision surgery is required, compared with medical management and treatment for comorbidities, bariatric surgery is cost-saving over an individual’s lifetime. These cost savings also include less time away from work and enhanced productivity.[46] Broader implementation of bariatric surgery faces significant scalability challenges, limiting its accessibility to a broader patient population that could benefit from this intervention.[47] Presently, less than 1% of eligible individuals in the United States undergo bariatric procedures.[48]
Enhancing Healthcare Team Outcomes
Obesity is most effectively treated within an interdisciplinary setting by subspecialty-trained professionals. A comprehensive team includes surgeons, anesthetists, obesity medicine specialists, primary care clinicians, endocrinologists, gastroenterologists, psychiatrists, psychologists, nutritionists, nurses, and physiotherapists. Achieving the best outcomes requires collaboration and communication, and the application of the medical pillars of beneficence, nonmaleficence, justice, and autonomy. Bariatric medicine is patient-centered, and safety is always at the forefront. The team that employs specialized training and operates under these principles has achieved improved outcomes.
References
Emmerich SD, Fryar CD, Stierman B, Ogden CL. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023. NCHS data brief. 2024 Sep:(508):. doi: 10.15620/cdc/159281. Epub [PubMed PMID: 39808758]
Islam ANMS, Sultana H, Nazmul Hassan Refat M, Farhana Z, Abdulbasah Kamil A, Meshbahur Rahman M. The global burden of overweight-obesity and its association with economic status, benefiting from STEPs survey of WHO member states: A meta-analysis. Preventive medicine reports. 2024 Oct:46():102882. doi: 10.1016/j.pmedr.2024.102882. Epub 2024 Sep 5 [PubMed PMID: 39290257]
Level 1 (high-level) evidenceDombrowski SU, Knittle K, Avenell A, Araújo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ (Clinical research ed.). 2014 May 14:348():g2646. doi: 10.1136/bmj.g2646. Epub 2014 May 14 [PubMed PMID: 25134100]
Level 1 (high-level) evidenceGloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, Bucher HC, Nordmann AJ. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ (Clinical research ed.). 2013 Oct 22:347():f5934. doi: 10.1136/bmj.f5934. Epub 2013 Oct 22 [PubMed PMID: 24149519]
Level 1 (high-level) evidenceKim JC, Kim MG, Park JK, Lee S, Kim J, Cho YS, Kong SH, Park DJ, Lee HJ, Yang HK. Outcomes and Adverse Events After Bariatric Surgery: An Updated Systematic Review and Meta-analysis, 2013-2023. Journal of metabolic and bariatric surgery. 2023 Dec:12(2):76-88. doi: 10.17476/jmbs.2023.12.2.76. Epub 2023 Dec 28 [PubMed PMID: 38196785]
Level 1 (high-level) evidenceHennekens CH, Andreotti F. Leading avoidable cause of premature deaths worldwide: case for obesity. The American journal of medicine. 2013 Feb:126(2):97-8. doi: 10.1016/j.amjmed.2012.06.018. Epub [PubMed PMID: 23331433]
Level 3 (low-level) evidenceZhao Y, Xie L, Chen T. Commentary on "Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study". Hepatology international. 2025 Nov 12:():. doi: 10.1007/s12072-025-10958-5. Epub 2025 Nov 12 [PubMed PMID: 41222619]
Level 2 (mid-level) evidenceDicker D, Sagy YW, Ramot N, Battat E, Greenland P, Arbel R, Lavie G, Reges O. Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality. JAMA network open. 2024 Jun 3:7(6):e2415392. doi: 10.1001/jamanetworkopen.2024.15392. Epub 2024 Jun 3 [PubMed PMID: 38848064]
Yousefi R, Ben-Porat T, Marques Vieira A, Lavoie KL, Bacon SL, REBORN Study Team. Who gains the most quality-of-life benefits from metabolic and bariatric surgery: findings from the prospective REBORN cohort study. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2024 Dec:20(12):1297-1305. doi: 10.1016/j.soard.2024.08.029. Epub 2024 Aug 30 [PubMed PMID: 39304457]
Level 2 (mid-level) evidenceEisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, de Luca M, Faria SL, Goodpaster KPS, Haddad A, Himpens JM, Kow L, Kurian M, Loi K, Mahawar K, Nimeri A, O'Kane M, Papasavas PK, Ponce J, Pratt JSA, Rogers AM, Steele KE, Suter M, Kothari SN. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obesity surgery. 2023 Jan:33(1):3-14. doi: 10.1007/s11695-022-06332-1. Epub [PubMed PMID: 36336720]
Mechanick JI, Apovian C, Brethauer S, Timothy Garvey W, Joffe AM, Kim J, Kushner RF, Lindquist R, Pessah-Pollack R, Seger J, Urman RD, Adams S, Cleek JB, Correa R, Figaro MK, Flanders K, Grams J, Hurley DL, Kothari S, Seger MV, Still CD. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures - 2019 Update: Cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Obesity (Silver Spring, Md.). 2020 Apr:28(4):O1-O58. doi: 10.1002/oby.22719. Epub [PubMed PMID: 32202076]
Level 1 (high-level) evidenceAderinto N, Olatunji G, Kokori E, Olaniyi P, Isarinade T, Yusuf IA. Recent advances in bariatric surgery: a narrative review of weight loss procedures. Annals of medicine and surgery (2012). 2023 Dec:85(12):6091-6104. doi: 10.1097/MS9.0000000000001472. Epub 2023 Nov 1 [PubMed PMID: 38098582]
Level 3 (low-level) evidenceZidan MH, Amgad A, Al Sayed M, Altabbaa H, El-Masry H, Bessa A, Abokhozima A. Advancements in Bariatric Surgery: A Novel Parametric Classification of Metabolic and Bariatric Procedures. Obesity surgery. 2025 Jan:35(1):4-6. doi: 10.1007/s11695-024-07646-y. Epub 2024 Dec 23 [PubMed PMID: 39714768]
Staudenmann DA, Sui Z, Saxena P, Kaffes AJ, Marinos G, Kumbhari V, Aepli P, Sartoretto A. Endoscopic bariatric therapies for obesity: a review. The Medical journal of Australia. 2021 Aug 16:215(4):183-188. doi: 10.5694/mja2.51179. Epub 2021 Aug 1 [PubMed PMID: 34333788]
Hedberg S, Thorell A, Österberg J, Peltonen M, Andersson E, Näslund E, Hertel JK, Svanevik M, Stenberg E, Neovius M, Näslund I, Wirén M, Ottosson J, Olbers T, BEST Study Group. Comparison of Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass: A Randomized Clinical Trial. JAMA network open. 2024 Jan 2:7(1):e2353141. doi: 10.1001/jamanetworkopen.2023.53141. Epub 2024 Jan 2 [PubMed PMID: 38289603]
Level 1 (high-level) evidenceStryhn K, Alstrup L, Riber C, Ørting M, Hadad R, Hvistendahl J, Tollund C, Boye N, Haugaard SB, Funch-Jensen P. Complications in Patients Undergoing Laparoscopic Bariatric Surgery in an ERABS-optimized, High-Volume, Single Center During 2020 and 2021. Obesity surgery. 2023 Jul:33(7):2064-2071. doi: 10.1007/s11695-023-06596-1. Epub 2023 May 18 [PubMed PMID: 37199830]
Cooper S, Patel S, Wynn M, Provost D, Hassan M. Outcomes of same-day discharge in bariatric surgery. Surgical endoscopy. 2024 Sep:38(9):5122-5129. doi: 10.1007/s00464-024-11053-w. Epub 2024 Jul 19 [PubMed PMID: 39028346]
Mahmood F, Sharples AJ, Rotundo A, Balaji N, Rao VSR. Factors Predicting Length of Stay Following Bariatric Surgery: Retrospective Review of a Single UK Tertiary Centre Experience. Obesity surgery. 2018 Jul:28(7):1924-1930. doi: 10.1007/s11695-017-3105-8. Epub [PubMed PMID: 29352753]
Level 2 (mid-level) evidenceMonteiro Delgado L, Fabretina de Souza V, Fontel Pompeu B, de Moraes Ogawa T, Pereira Oliveira H, Sacksida Valladão VDC, Lima Castelo Branco Marques FI. Long-Term Outcomes in Sleeve Gastrectomy versus Roux-en-Y Gastric Bypass: A Systematic Review and Meta-Analysis of Randomized Trials. Obesity surgery. 2025 Aug:35(8):3246-3257. doi: 10.1007/s11695-025-08044-8. Epub 2025 Jul 7 [PubMed PMID: 40622470]
Level 1 (high-level) evidenceParretti HM, Subramanian A, Adderley NJ, Abbott S, Tahrani AA, Nirantharakumar K. Post-bariatric surgery nutritional follow-up in primary care: a population-based cohort study. The British journal of general practice : the journal of the Royal College of General Practitioners. 2021 Jun:71(707):e441-e449. doi: 10.3399/bjgp20X714161. Epub 2021 May 27 [PubMed PMID: 33824163]
O'Kane M, Barth JH. Nutritional follow-up of patients after obesity surgery: best practice. Clinical endocrinology. 2016 May:84(5):658-61. doi: 10.1111/cen.13041. Epub 2016 Mar 11 [PubMed PMID: 26895813]
Kochis MA, Chinn JO, Nzenwa IC, Brennan KA, Pratt JSA, Griggs CL. Does the MBSAQIP Bariatric Surgical Risk/Benefit Calculator Accurately Predict Weight Loss in Adolescents? Obesity surgery. 2025 Oct 10:():. doi: 10.1007/s11695-025-08295-5. Epub 2025 Oct 10 [PubMed PMID: 41068350]
Level 2 (mid-level) evidenceAbuHasan Q, Chesnova B, Sanduka D, Saeidi S, Chang W, Yuce TK, Stefanidis D. Accuracy of the Metabolic and Bariatric Surgery Accreditation Quality Improvement Program risk/benefit calculator in predicting outcomes of revisional bariatric surgery. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2025 Dec:21(12):1326-1333. doi: 10.1016/j.soard.2025.06.019. Epub 2025 Aug 16 [PubMed PMID: 40975644]
Level 2 (mid-level) evidenceChalopin S, Bel Lassen P, Genser L, Aron-Wisnewsky J, Poitou C, Ciangura C, Torcivia A, Oppert JM, Bedock D, Faucher P. Management of Severe Malnutrition Post-bariatric Surgery Using Artificial Nutrition. Obesity surgery. 2024 Feb:34(2):363-370. doi: 10.1007/s11695-023-06842-6. Epub 2023 Dec 21 [PubMed PMID: 38123784]
David LA, Sijercic I, Cassin SE. Preoperative and post-operative psychosocial interventions for bariatric surgery patients: A systematic review. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2020 Apr:21(4):e12926. doi: 10.1111/obr.12926. Epub 2020 Jan 22 [PubMed PMID: 31970925]
Level 1 (high-level) evidenceReytor-González C, Frias-Toral E, Nuñez-Vásquez C, Parise-Vasco JM, Zambrano-Villacres R, Simancas-Racines D, Schiavo L. Preventing and Managing Pre- and Postoperative Micronutrient Deficiencies: A Vital Component of Long-Term Success in Bariatric Surgery. Nutrients. 2025 Feb 20:17(5):. doi: 10.3390/nu17050741. Epub 2025 Feb 20 [PubMed PMID: 40077612]
Lauti M, Kularatna M, Hill AG, MacCormick AD. Weight Regain Following Sleeve Gastrectomy-a Systematic Review. Obesity surgery. 2016 Jun:26(6):1326-34. doi: 10.1007/s11695-016-2152-x. Epub [PubMed PMID: 27048439]
Level 1 (high-level) evidenceSheets CS, Peat CM, Berg KC, White EK, Bocchieri-Ricciardi L, Chen EY, Mitchell JE. Post-operative psychosocial predictors of outcome in bariatric surgery. Obesity surgery. 2015 Feb:25(2):330-45. doi: 10.1007/s11695-014-1490-9. Epub [PubMed PMID: 25381119]
Çalık Başaran N, Dotan I, Dicker D. Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels. International journal of obesity (2005). 2025 Mar:49(3):412-417. doi: 10.1038/s41366-024-01461-2. Epub 2024 Jan 15 [PubMed PMID: 38225284]
Chetty AK, Rafi E, Bellini NJ, Buchholz N, Isaacs D. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2024 Mar:30(3):292-303. doi: 10.1016/j.eprac.2023.12.010. Epub 2023 Dec 18 [PubMed PMID: 38122931]
Esparham A, Mehri A, Dalili A, Richards J, Khorgami Z. Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2024 Nov:25(11):e13811. doi: 10.1111/obr.13811. Epub 2024 Aug 12 [PubMed PMID: 39134066]
Level 1 (high-level) evidenceBahardoust M, Ranjbarpazuki A, Shamohammadi M, Mousavi A, Yarahmadi D, Haghmoradi M, Goodarzy B, Garavand AA, Tizmaghz A. Predictors of Post-Bariatric Surgery Hypoglycemia: A Multicenter Retrospective Cohort Study. Endocrinology, diabetes & metabolism. 2025 Nov:8(6):e70123. doi: 10.1002/edm2.70123. Epub [PubMed PMID: 41206858]
Level 2 (mid-level) evidenceFarooqi S, Montrief T, Koyfman A, Long B. High risk and low incidence diseases: Bariatric surgery complications. The American journal of emergency medicine. 2025 Jan:87():113-122. doi: 10.1016/j.ajem.2024.10.050. Epub 2024 Nov 2 [PubMed PMID: 39561500]
Level 2 (mid-level) evidenceGoel R, Nasta AM, Goel M, Prasad A, Jammu G, Fobi M, Ismail M, Raj P, Palaniappan R, Aggarwal S, Bindal V, Katakwar A, Vennapusa A, Bhasker AG, Peters A, Goel D, Bedi D, Palep J, Kona L, Mehrotra M, Baijal M, Bhandari M, Dukkipati N, Wadhawan R, Baig S, Pattanshetti S, Ugale S. Complications after bariatric surgery: A multicentric study of 11,568 patients from Indian bariatric surgery outcomes reporting group. Journal of minimal access surgery. 2021 Apr-Jun:17(2):213-220. doi: 10.4103/jmas.JMAS_12_20. Epub [PubMed PMID: 32964881]
Miras AD, Kamocka A, Patel D, Dexter S, Finlay I, Hopkins JC, Khan O, Reddy M, Sedman P, Small P, Somers S, Cro S, Walton P, le Roux CW, Welbourn R. Obesity surgery makes patients healthier and more functional: real world results from the United Kingdom National Bariatric Surgery Registry. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2018 Jul:14(7):1033-1040. doi: 10.1016/j.soard.2018.02.012. Epub 2018 Feb 15 [PubMed PMID: 29778650]
Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and Risks of Bariatric Surgery in Adults: A Review. JAMA. 2020 Sep 1:324(9):879-887. doi: 10.1001/jama.2020.12567. Epub [PubMed PMID: 32870301]
Hallberg SJ, Gershuni VM, Hazbun TL, Athinarayanan SJ. Reversing Type 2 Diabetes: A Narrative Review of the Evidence. Nutrients. 2019 Apr 1:11(4):. doi: 10.3390/nu11040766. Epub 2019 Apr 1 [PubMed PMID: 30939855]
Level 3 (low-level) evidenceBuchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. The American journal of medicine. 2009 Mar:122(3):248-256.e5. doi: 10.1016/j.amjmed.2008.09.041. Epub [PubMed PMID: 19272486]
Level 1 (high-level) evidenceSyn NL, Cummings DE, Wang LZ, Lin DJ, Zhao JJ, Loh M, Koh ZJ, Chew CA, Loo YE, Tai BC, Kim G, So JB, Kaplan LM, Dixon JB, Shabbir A. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet (London, England). 2021 May 15:397(10287):1830-1841. doi: 10.1016/S0140-6736(21)00591-2. Epub 2021 May 6 [PubMed PMID: 33965067]
Level 1 (high-level) evidenceWiggins T, Guidozzi N, Welbourn R, Ahmed AR, Markar SR. Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: A systematic review and meta-analysis. PLoS medicine. 2020 Jul:17(7):e1003206. doi: 10.1371/journal.pmed.1003206. Epub 2020 Jul 28 [PubMed PMID: 32722673]
Level 1 (high-level) evidenceLi S, Zhang Y, Zhang Y, Xue J, Kang C. Assessment of changes in left ventricular myocardial work using the pressure strain loop after metabolic and bariatric surgery: a prospective nonrandomized cohort study. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2026 Jan:22(1):26-37. doi: 10.1016/j.soard.2025.08.027. Epub 2025 Oct 10 [PubMed PMID: 41198482]
Level 1 (high-level) evidenceMainra A, Abdallah SJ, Reid RER, Andersen RE, Jensen D. Effect of weight loss via bariatric surgery for class III obesity on exertional breathlessness. Respiratory physiology & neurobiology. 2019 Aug:266():130-137. doi: 10.1016/j.resp.2019.05.007. Epub 2019 May 14 [PubMed PMID: 31100374]
Dudek A, Zapała B, Żukowska-Żbik M, Orzechowska P, Kawa I, Ciszek K, Tylec P, Cyranka K, Wysocki M, Major P. The impact of metabolic bariatric surgery on biological markers of aging: a 2-year prospective observational study. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2025 Oct:21(10):1131-1140. doi: 10.1016/j.soard.2025.06.005. Epub 2025 Jun 18 [PubMed PMID: 40750489]
Level 2 (mid-level) evidenceNickel F, Schmidt L, Bruckner T, Büchler MW, Müller-Stich BP, Fischer L. Influence of bariatric surgery on quality of life, body image, and general self-efficacy within 6 and 24 months-a prospective cohort study. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2017 Feb:13(2):313-319. doi: 10.1016/j.soard.2016.08.017. Epub 2016 Aug 18 [PubMed PMID: 28029597]
Level 2 (mid-level) evidenceMadsen HJ, Gillette RA, Colborn KL, Henderson WG, Dyas AR, Bronsert MR, Lambert-Kerzner A, Meguid RA. The association between obesity and postoperative outcomes in a broad surgical population: A 7-year American College of Surgeons National Surgical Quality Improvement analysis. Surgery. 2023 May:173(5):1213-1219. doi: 10.1016/j.surg.2023.02.001. Epub 2023 Mar 3 [PubMed PMID: 36872175]
Level 2 (mid-level) evidenceXia Q, Campbell JA, Ahmad H, Si L, de Graaff B, Palmer AJ. Bariatric surgery is a cost-saving treatment for obesity-A comprehensive meta-analysis and updated systematic review of health economic evaluations of bariatric surgery. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2020 Jan:21(1):e12932. doi: 10.1111/obr.12932. Epub 2019 Nov 16 [PubMed PMID: 31733033]
Level 1 (high-level) evidenceMorissette A, Mulvihill EE. Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2024:27():13065. doi: 10.3389/jpps.2024.13065. Epub 2024 Jun 6 [PubMed PMID: 38903652]
Liao J, Yin Y, Zhong J, Chen Y, Chen Y, Wen Y, Cai Z. Bariatric surgery and health outcomes: An umbrella analysis. Frontiers in endocrinology. 2022:13():1016613. doi: 10.3389/fendo.2022.1016613. Epub 2022 Oct 28 [PubMed PMID: 36387921]